Viewing Study NCT06568692


Ignite Creation Date: 2025-12-24 @ 3:25 PM
Ignite Modification Date: 2026-02-25 @ 11:48 PM
Study NCT ID: NCT06568692
Status: RECRUITING
Last Update Posted: 2025-06-19
First Post: 2024-08-21
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Sponsor: Processa Pharmaceuticals
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Cancer View
None TNBC - Triple-Negative Breast Cancer View
None HER2-negative Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None HR positive View
None Advanced Breast Cancer View
None Metastatic Breast Cancer View